---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-010226"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2024-01-18T23:59:59+00:00"
generated_at: "2026-06-06T21:57:25.701819+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Spyre Therapeutics transfers listing to Nasdaq Global Select Market effective Jan 19, 2024

## Summary
- Received approval from Nasdaq to transfer listing from Capital Market to Global Select Market.
- Effective at the opening of business on January 19, 2024.
- Common stock continues to trade under the symbol SYRE.
- Transfer indicates the company met stricter financial requirements for higher-tier market.

## SEC filing metadata
- accession: 0001193125-24-010226
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2024-01-18T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312524010226/0001193125-24-010226-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312524010226/d700531d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-010226
- JSON: https://secwatch.observer/filing/0001193125-24-010226.json
- Plain text: https://secwatch.observer/filing/0001193125-24-010226.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.